HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today
announced that Aradigm management will present at the Ladenburg Thalmann
2017 Healthcare Conference on Tuesday, September 26, 2017, at 2:00 p.m.
ET. The event will be held at the Sofitel New York in New York, New York.
Interested parties can access a live audio webcast and slide
presentation at www.aradigm.com.
An archived presentation will be available on the Company's Web site for
Aradigm is an emerging specialty pharmaceutical company focused on the
development and commercialization of drugs for the prevention and
treatment of severe respiratory diseases. Aradigm has completed two
Phase 3 clinical trials with Linhaliq™, an investigational proprietary
formulation of ciprofloxacin for inhalation, for the treatment of NCFBE
and submitted a New Drug Application to the FDA for this indication.
Aradigm's inhaled ciprofloxacin formulations, including Linhaliq, are
also product candidates for treatment of patients with cystic fibrosis
and non-tuberculous mycobacteria, and for the prevention and treatment
of high threat and bioterrorism infections, such as inhaled tularemia,
pneumonic plague, melioidosis, Q fever and inhaled anthrax.
More information about Aradigm can be found at www.aradigm.com.
Aradigm and the Aradigm Logo are registered trademarks of Aradigm
View source version on businesswire.com: http://www.businesswire.com/news/home/20170922005090/en/
Nancy Pecota, 510-265-8800
Source: Aradigm Corporation
News Provided by Acquire Media